加速超分割放化疗序贯立体定向消融放疗增敏用于局部晚期、不可切除的非小细胞肺癌 - Suppr

Suppr

超能文献

Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer.

作者信息

Weber Urs M, Watson Alexander S, Kavanagh Brian D, Bunn Paul A

机构信息

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA.

出版信息

Transl Cancer Res. 2025 Feb 28;14(2):676-678. doi: 10.21037/tcr-24-1869. Epub 2025 Feb 26.

DOI:10.21037/tcr-24-1869

PMID:40104723

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912038/

Abstract

摘要

相似文献

Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer.

Transl Cancer Res. 2025 Feb 28;14(2):676-678. doi: 10.21037/tcr-24-1869. Epub 2025 Feb 26.

Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.

JAMA Oncol. 2024 Mar 1;10(3):352-359. doi: 10.1001/jamaoncol.2023.6033.

Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.

J Thorac Oncol. 2025 Jan;20(1):39-51. doi: 10.1016/j.jtho.2024.09.1437. Epub 2024 Sep 28.

Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.

J Thorac Oncol. 2017 Nov;12(11):1687-1695. doi: 10.1016/j.jtho.2017.07.036. Epub 2017 Sep 13.

Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806318. doi: 10.1177/1533033818806318.

Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial.

BMC Cancer. 2016 Apr 23;16:288. doi: 10.1186/s12885-016-2314-1.

Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer.

Transl Lung Cancer Res. 2021 Jan;10(1):529-538. doi: 10.21037/tlcr-2020-nsclc-04.

Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.

Radiother Oncol. 2024 Dec;201:110439. doi: 10.1016/j.radonc.2024.110439. Epub 2024 Jul 19.

Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.

Radiat Oncol. 2013 Aug 17;8(1):201. doi: 10.1186/1748-717X-8-201.

High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.

Radiat Oncol. 2013 Aug 11;8(1):198. doi: 10.1186/1748-717X-8-198.

本文引用的文献

Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.

JAMA Oncol. 2024 Mar 1;10(3):352-359. doi: 10.1001/jamaoncol.2023.6033.

The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC.

Radiother Oncol. 2024 Jan;190:110030. doi: 10.1016/j.radonc.2023.110030. Epub 2023 Nov 24.

Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors.

Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1435-1444. doi: 10.1016/j.ijrobp.2023.10.005. Epub 2023 Oct 21.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2.

Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617.

Cancers (Basel). 2021 Dec 8;13(24):6193. doi: 10.3390/cancers13246193.

Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.

Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):346-355. doi: 10.1016/j.ijrobp.2019.05.064. Epub 2019 Jun 5.

Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.

J Clin Oncol. 2019 May 20;37(15):1316-1325. doi: 10.1200/JCO.18.00622. Epub 2019 Apr 3.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

Late-Course Adaptive Adjustment Based on Metabolic Tumor Volume Changes during Radiotherapy May Reduce Radiation Toxicity in Patients with Non-Small Cell Lung Cancer.

PLoS One. 2017 Jan 26;12(1):e0170901. doi: 10.1371/journal.pone.0170901. eCollection 2017.

Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1228-34. doi: 10.1016/j.ijrobp.2008.10.054.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Accelerated hypofractionated chemoradiation followed by stereotactic ablative radiotherapy boost for locally advanced, unresectable non-small cell lung cancer.

作者信息

Weber Urs M, Watson Alexander S, Kavanagh Brian D, Bunn Paul A

机构信息

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA.

出版信息

Transl Cancer Res. 2025 Feb 28;14(2):676-678. doi: 10.21037/tcr-24-1869. Epub 2025 Feb 26.

DOI:10.21037/tcr-24-1869

PMID:40104723

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912038/

Abstract

摘要